Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.88 USD | +2.52% |
|
-7.75% | -64.99% |
06-28 | Verve Therapeutics, Inc. Announces Board Appointments | CI |
06-10 | Transcript : Verve Therapeutics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 08:00 AM |
Evolution of the average Target Price on Verve Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
![Consensus](/images/consensus_flch.gif)
Consensus detail
Consensus revision (last 18 months)
Analysts covering Verve Therapeutics, Inc.
Stifel Nicolaus | |
Guggenheim | |
Canaccord Genuity | |
Credit Suisse | |
Cantor Fitzgerald | |
Goldman Sachs | |
RBC Capital Markets | |
BMO Capital | |
JPMorgan Chase | |
Jefferies & Co. | |
William Blair & Co. |
EPS Revisions
- Stock Market
- Equities
- VERV Stock
- Consensus Verve Therapeutics, Inc.